Figure 5.

Additive anti-tumor activity of CD44NK cells in combination with cisplatin treatment. A2780 (A) and P3 (B) cells were treated for 4 days (cisplatin treatment for 72 h, NK-92 or CAR-NK-92 treatment 24 h) with the previously determined IC₅₀ dose of cisplatin and an E/T ratio of 2:1. Relative survival rate was calculated by dividing the results obtained from each group by the results of cisplatin monotherapy. Tumor cell loss of A2780 (C) and P3 (D) was calculated by dividing the results of CD44NK cells by the results of untransduced NK-92 cells for the designated conditions. * indicates a significant difference calculated by one-way ANOVA, p < 0.05. Values represent the mean from two separate experiments each containing three samples.